Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Assets (2023 - 2025)

Historic Current Assets for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $28.5 million.

  • BioLineRx's Current Assets fell 2463.74% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year decrease of 2463.74%. This contributed to the annual value of $27.1 million for FY2024, which is 4255.56% down from last year.
  • As of Q3 2025, BioLineRx's Current Assets stood at $28.5 million, which was down 2463.74% from $31.9 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Current Assets ranged from a high of $49.1 million in Q2 2024 and a low of $27.1 million during Q4 2024
  • Over the past 3 years, BioLineRx's median Current Assets value was $34.7 million (recorded in 2023), while the average stood at $36.1 million.
  • The largest annual percentage gain for BioLineRx's Current Assets in the last 5 years was 4156.0% (2024), contrasted with its biggest fall of 4255.56% (2024).
  • Quarter analysis of 3 years shows BioLineRx's Current Assets stood at $47.2 million in 2023, then plummeted by 42.56% to $27.1 million in 2024, then grew by 5.24% to $28.5 million in 2025.
  • Its Current Assets was $28.5 million in Q3 2025, compared to $31.9 million in Q2 2025 and $31.9 million in Q1 2025.